Letter: HCV Complication and Type 2 Diabetes Management-The Directional Link Is Not Yet Defined. Authors’ Reply

Alimentary Pharmacology and Therapeutics - United Kingdom
doi 10.1111/apt.15247
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Letter: HCV Complication and Type 2 Diabetes Management-The Directional Link Is Not Yet Defined

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

VLCD for Weight Loss and Remission of Type 2 Diabetes? – Authors' Reply

The Lancet
Medicine
2018English

Authors Reply Letter to the Reviewers

2020English

Editorial: Faecal Microbiota Transplantation for Ulcerative Colitis-Not Quite There Yet? Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

HCV and Diabetes: Towards a ‘Sustained’ Glycaemic Improvement After Treatment With DAAs? – Authors' Reply

Clinical Microbiology and Infection
MedicineInfectious DiseasesMicrobiology
2017English

Sugar Consumption and Diabetes (The Authors Reply)

Journal of Chemical Education
ChemistryEducation
1933English

Letter: Overcoming Secondary Loss of Response to Infliximab-It Is Not the Drug, It Is How You Use It! Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Editorial: Not Yet Time for Universal Susceptibility-Guided First-Line Helicobacter Pylori Treatment-Authors' Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Letter: The Efficacy of Interferon-Free Regimens in HCV-related Child C Cirrhosis Needs Careful Interpretation―Authors' Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy